[en] A clinical isolate of Pseudomonas aeruginosa recovered from the lower respiratory tract of an 81-year-old patient hospitalized in Belgium was sent to the national reference center to determine its resistance mechanism. PCR sequencing identified a new GES variant, GES-18, which differs from the carbapenem-hydrolyzing enzyme GES-5 by a single amino acid substitution (Val80Ile, in the numbering according to Ambler) and from GES-1 by two substitutions (Val80Ile and Gly170Ser). Detailed kinetic characterization showed that GES-18 and GES-5 hydrolyze imipenem and cefoxitin with similar kinetic parameters and that GES-18 was less susceptible than GES-1 to classical β-lactamase inhibitors such as clavulanate and tazobactam. The overall structure of GES-18 is similar to the solved structures of GES-1 and GES-2, the Val80Ile and Gly170Ser substitutions causing only subtle local rearrangements. Notably, the hydrolytic water molecule and the Glu166 residue were slightly displaced compared to their counterparts in GES-1. Our kinetic and crystallographic data for GES-18 highlight the pivotal role of the Gly170Ser substitution which distinguishes GES-5 and GES-18 from GES-1.
Bogaerts P, Naas T, El Garch F, Cuzon G, Deplano A, Delaire T, Huang TD, Lissoir B, Nordmann P, Glupczynski Y. 2010. GES extended-spectrum β-lactamases in Acinetobacter baumannii isolates in Belgium. Antimicrob. Agents Chemother. 54:4872-4878.
Bonnin RA, Nordmann P, Potron A, Lecuyer H, Zahar JR, Poirel L. 2011. Carbapenem-hydrolyzing GES-type extended spectrum β-lactamase in Acinetobacter baumannii. Antimicrob. Agents Chemother. 55:349-354.
Moubareck C, Brémont S, Conroy MC, Courvalin P, Lambert T. 2009. GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob. Agents Chemother. 53:3579-3581.
Naas T, Poirel L, Nordmann P. 2008. Minor extended-spectrum β-lactamases. Clin. Microbiol. Infect. 14:42-52.
Pasteran F, Faccone D, Petroni A, Rapoport M, Galas M, Vázquez M, Procopio A. 2005. Novel variant (bla(VIM-11)) of the metallo-β-lactamase bla(VIM) family in a GES-1 extended-spectrum-β-lactamase-producing Pseudomonas aeruginosa clinical isolate in Argentina. Antimicrob. Agents Chemother. 49:474-475.
Picão RC, Poirel L, Gales AC, Nordmann P. 2009. Diversity of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. Antimicrob. Agents Chemother. 53:3908-3913.
Poirel L, Weldhagen GF, De Champs C, Nordmann P. 2002. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum β-lactamase GES-2 in South Africa. J. Antimicrob. Chemother. 49:561-565.
Wang J, Zhou JY, Qu TT, Shen P, Wei ZQ, Yu YS, Li LJ. 2010. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals. Int. J. Antimicrob. Agents 35:486-491.
Viedma E, Juan C, Acosta J, Zamorano L, Otero JR, Sanz F, Chaves F, Oliver A. 2009. Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum β-lactamases GES-1 and GES-5 in Spain. Antimicrob. Agents Chemother. 53:4930-4933.
Kotsakis SD, Papagiannitsis CC, Tzelepi E, Legakis NJ, Miriagou V, Tzouvelekis LS. 2010. GES-13, a β-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:1331-1333.
Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. 2000. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 44:622-632.
Ambler RP, Coulson AF, Frère JM, Ghuysen JM, Joris B, Forsman M, Levesque RC, Tiraby G, Waley SG. 1991. A standard numbering scheme for the class A β-lactamases. Biochem. J. 276:269-270.
Smith CA, Caccamo M, Kantardjieff KA, Vakulenko S. 2007. Structure of GES-1 at atomic resolution: insights into the evolution of carbapenemase activity in the class A extended-spectrum β-lactamases. Acta Crystallogr. Sect. D 63:982-992.
Bae IK, Lee YN, Jeong SH, Hong SG, Lee JH, Lee SH, Kim HJ, Youn H. 2007. Genetic and biochemical characterization of GES-5, an extended-spectrum class A β-lactamase from Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 58:465-468.
Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. 2001. GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob. Agents Chemother. 45:2598-2603.
Vourli S, Giakkoupi P, Miriagou V, Tzelepi E, Vatopoulos AC, Tzouvelekis LS. 2004. Novel GES/IBC extended-spectrum β-lactamase variants with carbapenemase activity in clinical enterobacteria. FEMS Microbiol. Lett. 234:209-213.
Wachino J, Doi Y, Yamane K, Shibata N, Yagi T, Kubota T, Arakawa Y. 2004. Molecular characterization of a cephamycin-hydrolyzing and inhibitor-resistant class A β-lactamase, GES-4, possessing a single G170S substitution in the omega-loop. Antimicrob. Agents Chemother. 48:2905-2910.
Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Riezer J, Saier MH, Hancock RE, Lory S, Olson MV. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959-964.
Jacoby GA. 1974. Properties of R plasmids determining gentamicin resistance by acetylation in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 6:239-252.
Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing. CLSI M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
Naas T, Cuzon G, Bogaerts P, Glupczynski Y, Nordmann P. 2011. Evaluation of a DNA microarray (Check-MDR CT102) for rapid detection of TEM, SHV, and CTX-M extended-spectrum β-lactamases and of KPC, OXA-48, VIM, IMP, and NDM-1 carbapenemases. J. Clin. Microbiol. 49:1608-1613.
Lévesque C, Piché L, Larose C, Roy PH. 1995. PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob. Agents Chemother. 39:185-191.
Kieser T. 1984. Factors affecting the isolation of CCC DNA from Streptomyces lividans and Escherichia coli. Plasmid 12:19-36.
Delbrück H, Bogaerts P, Kupper MB, Rezende de Castro R, Bennink S, Glupczynski Y, Galleni M, Hoffmann KM, Bebrone C. 2012. Kinetic and crystallographic studies of extended spectrum GES-11, GES-12 and GES-14 β-lactamases. Antimicrob. Agents Chemother. 56:5618-5625.
Cornish-Bowden A. 2001. Fundamentals of enzyme kinetics. Portland Press Ltd., London, United Kingdom.
Frase H, Shi Q, Testero SA, Mobashery S, Vakulenko SB. 2009. Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of β-lactamases. J. Biol. Chem. 284:29509-29513.
Kabsch W. 1993. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 26:795-800.
Collaborative Computational Project Number 4. 1994. CCP4 suite: programs for protein crystallography. Acta Crystallogr. Sect. D 50:760-763.
Perrakis A, Morris R, Lamzin VS. 1999. Automated protein model building combined with iterative structure refinement. Nat. Struct. Biol. 6:458-463.
Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D 60:2126-2132.
Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect. D 53:240-255.
Painter J, Merritt EA. 2006. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. Sect. D 62:439-450.
Moura A, Soares M, Pereira C, Leitao N, Henriques I, Correia A. 2009. INTEGRALL: a database and search engine for integrons, integrases and gene cassettes. Bioinformatics 25:1096-1098.
Laskowski RA, MacArthur MW, Moss DS, Thornton JM. 1993. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26: 283-291.
Frase H, Smith CA, Toth M, Champion MM, Mobashery S, Vakulenko SB. 2011. Identification of products of inhibition of GES-2 β-lactamase by tazobactam by X-ray crystallography and spectrometry. J. Biol. Chem. 286:14396-14409.
Drawz SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 23:160-201.
Golemi-Kotra D, Meroueh SO, Kim C, Vakulenko SB, Bulychev A, Stemmler AJ, Stemmler TL, Mobashery S. 2004. The importance of a critical protonation state and the fate of the catalytic steps in class A β-lactamases and penicillin-binding proteins. J. Biol. Chem. 279:34665-34673.
Kotsakis SD, Miriagou V, Tzelepi E, Tzouvelekis LS. 2010. Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. Antimicrob. Agents Chemother. 54:4864-4871.
Meroueh SO, Fisher JF, Schlegel HB, Mobashery S. 2005. Ab initio QM/MM study of class A β-lactamase acylation: dual participation of Glu166 and Lys73 in a concerted base promotion of Ser70. J. Am. Chem. Soc. 127:15397-15407.
Pérez-Llarena FJ, Kerff F, Abián O, Mallo S, Fernández MC, Galleni M, Sancho J, Bou G. 2011. Distant and new mutations in CTX-M-1 β-lactamase affect cefotaxime hydrolysis. Antimicrob. Agents Chemother. 55:4361-4368.
Frase H, Toth M, Champion MM, Antunes NT, Vakulenko SB. 2011. Importance of position 170 in the inhibition of GES-type β-lactamases by clavulanic acid. Antimicrob. Agents Chemother. 55:1556-1562.